<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043004</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40004</org_study_id>
    <secondary_id>EORTC-40004</secondary_id>
    <secondary_id>ALM-CAO-EORTC-40004</secondary_id>
    <secondary_id>NCRI-EORTC-40004</secondary_id>
    <nct_id>NCT00043004</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer</brief_title>
  <official_title>CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgruppe Lebermetastasen und Tumoren</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth
      in different ways. Some block the ability of tumor cells to grow and spread by blocking blood
      flow. Others find tumor cells and help kill them or carry tumor-killing substances to them.
      Radiofrequency ablation uses high-frequency electric current to kill tumor cells. It is not
      yet known if chemotherapy is more effective with or without radiofrequency ablation in
      treating liver metastases.

      PURPOSE: This randomized phase II trial is studying combination chemotherapy, bevacizumab,
      and radiofrequency ablation to see how well they work compared to combination chemotherapy
      and bevacizumab alone in treating unresectable liver metastases in patients with colorectal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the 30-month overall survival rate of patients with unresectable liver
           metastases secondary to colorectal adenocarcinoma treated with chemotherapy and
           bevacizumab with or without radiofrequency interstitial ablation.

      Secondary

        -  Compare overall survival of patients treated with these regimens.

        -  Compare quality of life of patients treated with these regimens.

        -  Determine the health economics associated with this study.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to treatment center, prior adjuvant chemotherapy for primary cancer (yes vs no),
      prior chemotherapy for liver metastases (yes vs no), and route of randomization (before
      surgery vs during surgery). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Within 4 weeks of randomization, patients undergo radiofrequency interstitial
           ablation (RFA) with or without additional resection of resectable lesions. Within 8
           weeks after RFA, patients receive chemotherapy and bevacizumab.

        -  Arm II: Within 4 weeks of randomization, patients receive chemotherapy and bevacizumab.

      In both arms, treatment continues in the absence of disease progression or unacceptable
      toxicity.

      Patients in both arms receive one of the following chemotherapy and bevacizumab regimens to
      be determined by participating center:

        -  Regimen A: Patients receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5
           and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 24
           hours on day 1 of weeks 1-6 and bevacizumab IV over 30-90 minutes on days 1 or 2, 15 or
           16, and 29 or 30. Treatment repeats every 7 weeks for 4 courses.

        -  Regimen B: Patients receive oxaliplatin IV and leucovorin calcium IV over 2 hours on day
           1 followed by fluorouracil IV continuously over 46 hours and bevacizumab IV over 30-90
           minutes on day 1 or 3. Treatment repeats every 15 days for 12 courses.

        -  Regimen C: Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium
           IV over 2 hours followed by fluorouracil IV continuously over 22 hours on days 1 and 2
           and bevacizumab IV over 30-90 minutes on day 1 or 3. Treatment repeats every 15 days for
           12 courses.

      Quality of life is assessed at baseline, within 1 week after completion of RFA (arm I only),
      within 1 week before start of chemotherapy (arm I only), at weeks 6, 12, 18, and 24 during
      chemotherapy, every 3 months for 2 years after treatment, and then every 6 months thereafter.

      After completion of study treatment, patients are followed every 3 months for 2Â½ years and
      then every 6 months thereafter.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: A total of 152 patients (71 per treatment arm) will be accrued for this
      study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate as measured by Kaplan Meier method at 30 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival as measured by Logrank every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTC version 2.0 every 3 months for 30 months then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) version 3.0 at baseline, weeks 6, 12, 18, and 24, every 3 months for years 1-2 after start of treatment, then every 6 months thereafter</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression</measure>
  </secondary_outcome>
  <enrollment type="Actual">119</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Unresectable liver metastases secondary to colorectal adenocarcinoma, including:

               -  Metastases that cannot be radically resected due to size, location, or number of
                  deposits

               -  Metastases invading right and left branches of hepatic artery or portal vein

               -  Metastases extended to the 3 main hepatic veins

          -  No detectable extra-hepatic disease

          -  Fewer than 10 metastatic deposits on liver

          -  Total metastatic involvement of liver no more than 50%

          -  Adequate treatment of all metastatic lesions deemed possible either by radiofrequency
             interstitial ablation (RFA) alone or by a combination of resection of resectable
             lesions and RFA of the remaining unresectable lesions

               -  Maximum diameter of 4 cm for lesions to be treated with RFA

               -  No maximum diameter of lesions to be resected as long as negative resection
                  margins are obtainable

          -  If synchronous liver metastases, must have undergone prior resection of primary tumor

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 80

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  No bleeding disorder or coagulopathy or need for full-dose anticoagulation

        Hepatic

          -  Bilirubin less than 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 3 times ULN

        Renal

          -  Creatinine less than 2 times ULN

          -  Protein &lt; 0.5 g/24 hr urine collection if proteinuria positive by dipstick

        Cardiovascular

          -  No uncontrolled congestive heart failure

          -  No uncontrolled angina pectoris

          -  No uncontrolled hypertension

          -  No uncontrolled arrhythmia

          -  No myocardial infarction within the past 12 months

          -  No cerebrovascular accident or transient ischemic attack within the past 6 months

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No greater than grade 1 peripheral neuropathy

          -  No significant neurologic or psychiatric disorder

          -  No active infection

          -  No contraindication to the use of fluorouracil, leucovorin calcium, oxaliplatin, or
             bevacizumab

          -  No other malignancy within the past 10 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy except for metastatic disease confined to the liver

               -  Prior fluorouracil, leucovorin calcium, and oxaliplatin allowed if administered
                  for at least 3 courses (2 weeks each) but no longer than 3 months with at least
                  stabilization of disease achieved

          -  Prior adjuvant chemotherapy for primary cancer allowed except for patients who
             received oxaliplatin and have been diagnosed with metastatic disease within 12 months
             after completion of adjuvant treatment

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  More than 28 days since major surgery or open biopsy past 28 days

          -  More than 28 days since significant traumatic injury

        Other

          -  No other concurrent investigational treatment

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Ruers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolf O. Bechstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arbeitsgruppe Lebermetastasen und Tumoren</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan A. Ledermann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire De Mont-Godinne</name>
      <address>
        <city>Mont-Godinne Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Cairo</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise Pare - Boulogne</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <zip>D-45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo-Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis - locatie Langendijk</name>
      <address>
        <city>Breda</city>
        <zip>4800 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Centre - Heerlen</name>
      <address>
        <city>Heerlen</city>
        <zip>6401 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden - Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital at Gothenburg University</name>
      <address>
        <city>Gothenburg (Goteborg)</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S - 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L69 3GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and University College London Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal South Hants Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO14 0YG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clywd District General Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ruers T, van Coevorden F, Pierie J, et al.: Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). [Abstract] J Clin Oncol 26 (Suppl 15): A-9535, 2008.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

